Most conversations about hormone therapy start the same way: a patient is miserable from hot flashes, night sweats, or mood swings, and hormone therapy comes up as a way to feel better. That conversation is important — but it's incomplete. A growing body of research suggests that hormone therapy started during perimenopause, before symptoms force the issue, may do something bigger than relieve discomfort: it may help protect your bones, mood, metabolism, and pelvic health for years to come.
This is often called the "window of opportunity" — and the timing turns out to matter more than many people realize.
Why timing is the whole story
The idea isn't that hormone therapy is only useful early on. It's that several of the changes menopause sets in motion - in bone, brain, metabolic, and pelvic tissue, begin during perimenopause, often years before your final period. By the time symptoms are severe enough to prompt a doctor's visit, some of that groundwork has already been laid. Starting the conversation earlier means starting protection earlier, and in several of these areas, research suggests the benefit is strongest when treatment begins close to the start of the transition rather than years after it ends.
Here are five areas where that timing appears to matter most.
1. Bone health
Most people assume bone loss is a postmenopausal problem. It isn't, it starts earlier than that. Research tracking women through the menopause transition has found that the a steep drop in bone density happens in the roughly two years before your final menstrual period, not after it. That means significant bone loss can already be underway during perimenopause, while your periods are still happening, just becoming irregular.
Starting hormone therapy during this window, rather than waiting until after menopause when a bone scan reveals a problem, gives estrogen a chance to help preserve the bone density you already have, instead of trying to rebuild what's already been lost.
2. Mood and mental health
Perimenopause is one of the highest-risk windows in a woman's life for new or worsening depression and anxiety, even among women with no prior history of either. This isn't just anecdotal: a randomized controlled trial published in JAMA Psychiatry found that transdermal estradiol combined with micronized progesterone significantly reduced the development of depressive symptoms in perimenopausal women compared with placebo.
What's notable is the timing effect: this protective benefit has been most clearly demonstrated during the menopause transition. The evidence for the same benefit after menopause has been established is less consistent, another argument for having this conversation earlier rather than later, particularly if mood changes are already showing up.
3. Metabolic health
Insulin resistance, the earliest step on the path toward type 2 diabetes, doesn't wait for menopause to begin. Metabolic shifts, including changes in how your body handles blood sugar and where it stores fat, start showing up during perimenopause, driven by the same hormonal shifts responsible for other symptoms.
Research, including a recent meta-analysis highlighted by The Menopause Society, has found that hormone therapy can meaningfully reduce insulin resistance, and separate research has shown it can lower the likelihood of progressing from prediabetes to diabetes in perimenopausal women. Starting earlier means intervening before insulin resistance has had years to compound.
4. Vaginal and urinary health
Vaginal dryness, discomfort, and recurrent urinary tract infections are often thought of as a postmenopausal problem, but tissue changes from declining estrogen can begin during perimenopause. Left unaddressed, these changes tend to progress rather than resolve on their own.
Starting local or systemic estrogen earlier can prevent that progression in the first place. Waiting, on the other hand, usually means treating damage that's already occurred rather than preventing it, a distinction worth understanding before symptoms become disruptive.
5. Brain health
This is the newest and most actively studied piece of the puzzle. A 2026 autopsy-based study led by researchers at Stanford found that women who had used estrogen-based hormone therapy showed roughly 35% fewer of the brain changes associated with Alzheimer's disease compared with women who hadn't. The researchers also found that women who started therapy closer to the onset of menopause showed the strongest association with lower Alzheimer's pathology.
A few important caveats worth passing along to patients: this was an observational autopsy study, not a randomized controlled trial, so it shows an association rather than definitive proof that hormone therapy prevents Alzheimer's — and the benefit was specifically tied to estrogen-based therapy. Researchers themselves have been clear that more study is needed before drawing firm conclusions. Still, it adds to a growing body of evidence that when hormone therapy starts may matter as much as whether it starts at all, and it's a compelling reason to bring brain health into the conversation earlier.
The bottom line
Hormone therapy is still, first and foremost, one of the most effective tools we have for hot flashes, night sweats, sleep disruption, and other perimenopausal symptoms. But the research increasingly points to something beyond symptom relief: bone density, mood stability, metabolic health, pelvic tissue health, and possibly long-term brain health may all be shaped, in part, by decisions made during perimenopause, not years later.
That doesn't mean hormone therapy is right for every person, or that starting later means it's too late to benefit. It does mean that perimenopause deserves to be treated as a proactive window, not just a waiting room for symptoms to arrive. If you're in your late 30s, 40s, or early 50s and haven't had this conversation yet, it's worth starting now, before the symptoms force the issue.